Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2007-11-09
2010-10-26
Kapushoc, Stephen (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091200, C536S023500, C536S024310
Reexamination Certificate
active
07820388
ABSTRACT:
The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. Also provided are probes for detecting the mutant sequences. Methods of identifying if an individual has a genotype containing one or more mutations in the CFTR gene are further provided.
REFERENCES:
patent: 4683194 (1987-07-01), Saiki et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4956778 (1990-09-01), Naito
patent: 4998617 (1991-03-01), Ladd, Jr. et al.
patent: 5130238 (1992-07-01), Malek et al.
patent: 5169766 (1992-12-01), Schuster et al.
patent: 5846710 (1998-12-01), Bajaj
patent: 5885775 (1999-03-01), Haff et al.
patent: 5888819 (1999-03-01), Goelet et al.
patent: 5955377 (1999-09-01), Maul et al.
patent: 5981178 (1999-11-01), Tsui et al.
patent: 5981714 (1999-11-01), Cheng et al.
patent: 6011588 (2000-01-01), Kim
patent: 6288220 (2001-09-01), Kambara et al.
patent: 6355429 (2002-03-01), Nygren et al.
patent: 6403320 (2002-06-01), Read et al.
patent: 6406844 (2002-06-01), Pirrung et al.
patent: 6812339 (2004-11-01), Venter et al.
patent: 2003/0235834 (2003-12-01), Dunlop et al.
patent: 2004/0110138 (2004-06-01), Lem et al.
patent: 2004/0126760 (2004-07-01), Broude
patent: 2005/0059035 (2005-03-01), Huang et al.
patent: 2008/0171332 (2008-07-01), Sun et al.
patent: 0 237362 (1992-03-01), None
patent: 0 329822 (1994-06-01), None
patent: 0 201184 (2004-08-01), None
patent: WO 88/10315 (1988-12-01), None
patent: WO 89/06700 (1989-07-01), None
patent: WO 2004/040013 (2004-05-01), None
Weiss, Fu et al. Complete cystic fibrosis transmembrane conductance regulator gene sequencing in patients with idiopathic chronic pancreatitis and controls. 2005. Gut vol. 54:1456-1460.
Castellani, C et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008. Journal of cystic Fibrosis. vol. 7 pp. 179-196.
Rowntree, Rebecca et al. The phenotypic consequences of CFTR mutations. 2003. Annals of Human Genetics. vol. 67 pp. 471-485.
Audrézet, et al., “Genomic Rearrangements in the CFTRGene: Extensive Allelic Heterogeneity and Diverse Mutational Mechanisms”Hum Mutat. 23(4):343-357 (2004).
Boat, et al., “The Metabolic Basis of Inherited Disease”Membrane Transport Systems, 6th ed, 2649-2680 (1989).
Carvalho-Oliveira, et al., “CFTR Localization in Native Airway Cells and Cell Lines Expressing Wild-type of F508del-CFTR by a Panel of Different Antibodies”, Journal of Histochemistry & Cytochemistry, 52(2): 193-203, (2004).
Claass, et al, “Applicability of Different Antibodies for Immunohistochemical Localization of CFTR in Sweat Glands from Healthy Controls and from Patients with Cystic Fibrosis”, The Journal of Histochemistry & Cytochemistry, 48(6): 831-837, (2000).
Cohn, et al., “CFTR: Development of High-Affinity Antibodies and Localization in Sweat Gland”, Biochemical and Biophysical Research Communications, 181(1): 36-43, (1991).
Doucet, et al., “Applicability of Different Antibodies for the Immunohistochemical Localization of CFTR in Respiratory and Intestinal Tissues of Human and Murine Origin”, 51(9): 1191-1199, (2003).
Flanigan, et al., “Rapid Direct Sequence Analysis of the Dystrophin Gene”, Am. J. Genet, 72:931-939, (2003).
Hoogendoorn, et al., “Genotyping Single Nucleotide Polymorphisms by Primer Extension and High Performance Liquid Chromatography”Human Genetics104;:89-93 (1999).
Jenison, et al., “Use of a Thin Film Biosensor for Rapid Visual Detection of PCR Products in a Multiplex Format”Biosens Bioelectron16(9-12):757-763 (2001).
Kwoh, et al., “Transcription-Based Amplification System and Detection of Amplified Human Immunodeficiency Virus Type 1 with a Bead-Based Sandwhich Hybridization Format”Proc. Natl. Acad. Sci. (USA) 86:1173-1177 (1989).
Landegren, et al., “A Ligase-Mediated Gene Detection Technique”Science241:1077-1080 (1988).
Endes, et al., “Antibodies in CFTR Studies”, Journal of Cystic Fibrosis, 3: 69-72, (2004).
Newton, et al., “Analysis of any Point Mutation in DNA. The Amplification Refractory Mutation System (ARMS)”Nucleic Acids Res. 17:2503-2516 (1989).
Nickerson, et al., “Automated DNA Diagnostics Using an ELISA-Based Oligonucleotide Litigate Assay”Proc. Natl. Acad. Sci. USA87:8923-8927 (1990).
Okayama, et al., “Rapid, nonradioactive detection of mutations in the human genome by allele-specific amplification”, J. Lab. Clin. Med., 114:105-113, (1989).
Piggee, et al., “Capillary Electrophoresis for the Detection of Known Point Mutations by Single-Nucleotide Primer Extension and Laster-Induced Fluorescence Detection”Journal of Chromatography A781:367-375 (1997).
Poddar, S.K., “Symmetric vs Asymmetric PCR and Molecular Beacon Probe in the Detection of a Target Gene of Adenovirus”Molec. and Cell. Probes14:25-32 (2000).
Sarkar, et al., “Characterization of Polymerase Chain Reaction Amplification of Specific Alleles”Anal. Biochem. 186:64-68 (1990).
Sellner, et al., “MLPA and MAPH: New Techniques for Detection of Gene Deletions”Human Mutation23:413-419 (2004).
Strom, et al., “Extensive sequencing of the cystic fibrosis transmembrane regulator gene: Assay validation and unexpected benefits of developing a comprehensive test”, Genetics in Medicine, 5(1):9-14, (2003).
Wall, et al. “A 31-Mutation Assay for Cystic Fibrosis Testing in the Clinical Molecular Diagnostics Laboratory”Human Mutation5(4):333-338 (1995).
Walker, et al., “Isothermal in Vitro Amplification of DNA by a Restriction Enzyme/DNA Polymerase System”Proc. Natl. Acad. Sci. USA89:392-396 (1992).
Walker, et al., “Production and characterisation of monoclonal and polyclonal antibodies to different regions of the cystic fibrosis transmembrane conductance regulator (CFTR): detection of immunologically related proteins”, Journal of Cell Science.
Wu, et al., “Allele-Specific Enzymatic Amplification of β-Globin Genomic DNA for Diagnosis of Sickle Cell Anemia”Proc. Natl. Acad. Sci. USA86:2757-2760 (1989).
Zielenski, et al., “Genomic DNA Sequence of the Cystic Fibrosis Transmembrane Conductane Regulator (CFTR) Gene”Genomics10:214-228 (1991).
Accession No. AY183426, published on Jan. 27, 2003.
Accession No. AF205406, published on Apr. 16, 2004.
Ratjen and Doring, Cystic Fibrosis, The Lancet, 361:681-689, 2003.
Chevalier-Porst et al, Identification of three rare frameshift mutations in exon 13 of the cystic fibrosis gene: 1918delGC, 2118del4 and 2373del8, Human Molecular Genetics, 2(7): 1071-1072, 1993.
Ezquieta et al, CF2603/4delT , a new frameshift mutation in exon 13 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Human Genetics, 91:614-615, 1993.
Hantash, F. et al., Consultations in Molecular Diagnostics. Characterization of a Recurrent Novel Large Duplication in the Cystic Transmembrane Conductance Regulator Gene. The Journal of Molecular Diagnostics, vol. 9, No. 4, Sep. 2007, p. 556-560.
Interview Summary dated Sep. 2, 2009 for U.S. Appl. No. 11/615,645.
Romey et al, Two novel rare frameshift mutations (2424 del G in exon 13 and 1215 del G in exon 7) and one novel rare sequence variation (3271 + 18 C or T) identified in a patient with cystic fibrosis. Human Molecular Genetics, 3(6): 1003-1004, 1994.
U.S. Final Office Action for U.S. Appl. No. 11/506,453 dated Jun. 6, 2008.
U.S. Final Office Action for U.S. Appl. No. 11/506,453 dated Sep. 16, 2009.
U.S. Office Action dated Jun. 13, 2008 for U.S. Appl. No. 11/615,645.
U.S. Office Action dated Jun. 26, 2009 for U.S. Appl. No. 11/615,645.
U.S. Office Action dated Aug. 8, 2007 for U.S. Appl. No. 11/506,453.
U.S. Office Action dated Oct. 31, 2007 for U.S. Appl. No. 11/506,453.
U.S. Office Action dated Nov. 24, 2008 for U.S. Appl. No. 11/615,645.
U.S. Office Action dated Dec. 11, 2008 for U.S. Appl. No.
Buller Arlene
Fenwick Raymond
Huang Donghui
McGinniss Matthew J.
Peng Mei
Foley & Lardner LLP
Kapushoc Stephen
Quest Diagnostics Investments Incorporated
Shaw Amanda
LandOfFree
Cystic fibrosis transmembrane conductance regulator gene... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cystic fibrosis transmembrane conductance regulator gene..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cystic fibrosis transmembrane conductance regulator gene... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4155164